Anti-PD-1 Drug Opdivo Significantly Improves Five Year Survival In Advanced Cancers

A new report from researchers at the Johns Hopkins Kimmel Cancer Center in Baltimore has shown impressive improvements in five-year survival for people with several types of advanced cancer treated with multiple doses of anti-PD-1 drug nivolumab.